Tag: covid-19 diagnosis

1. Older age, male sex, and pre-existing comorbidities were independent risk factors for developing complications following COVID-19 infection. 2. The most common complications included renal, complex respiratory, systemic, and cardiovascular. Evidence Rating Level: 2 (Good)  Study Rundown: Patients hospitalized with COVID-19 are likely to develop in-hospital complications which may worsen their prognosis....
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual care). 2. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Convalescent plasma is a...
1. In-hospital mortality within 30 days of admission for COVID-19 was 48% (vs. global mortality 31.5%). 2. Increased age, underlying comorbidities and delay in admission were associated with an increased mortality rate among African patients. Evidence Rating Level: 2 (Good) Study Rundown: The COVID-19 pandemic has exposed long-standing inequities in healthcare. Critically...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Participants identifying as South Asian or Black were more likely to test positive for COVID-19 infection, be hospitalized for COVID-related symptoms, and be admitted to the intensive care unit compared with the White population. 2. In the second wave, the relative rates of COVID-related hospitalization, ICU admission, and death...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. Analysis of the two distinct waves of the COVID-19 pandemic in Africa showed a more severe second wave with less stringent public health measures in place. 2. The pandemic had a diverse effect on the different regions of Africa, such as an increased prevalence of cases in the Southern...